STAT+: Microdosing aims to extend the lifespan of the GLP-1 compounding marketSTAT+: Microdosing aims to extend the lifespan of the GLP-1 compounding market
Noom, Found, and Hims & Hers have all launched programs to prescribe “microdosed” GLP-1s in the last three months, following in the footsteps of many smaller direct-to-consumer telehealth companies. Microdosing is getting a shot of promotion from Hollywood, too: Noom has promoted its program alongside a new celebrity spokesperson, actor Rebel Wilson, and TV host Read More
Bariatric Surgery May Cut Costs and Weight More Than GLP-1 DrugsBariatric Surgery May Cut Costs and Weight More Than GLP-1 Drugs
Despite growing prescription numbers and spending on glucagon-like peptide 1 (GLP-1) receptor agonists for obesity treatment, metabolic bariatric surgery may result in greater weight loss and lower costs, according to a recent study in JAMA Surgery. This comes as obesity experts have noticed decreased demand for the weight-loss surgery, which is often considered the “last Read More
Study shows semaglutide, tirzepatide and dulaglutide have similar gastrointestinal safety profiles in clinical settingsStudy shows semaglutide, tirzepatide and dulaglutide have similar gastrointestinal safety profiles in clinical settings
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the medications have similar gastrointestinal safety profiles among those with T2D, providing clinicians with evidence to weigh the risks and benefits of these medications for their patients. Read More
GI Risks Similar Among GLP-1 Drugs, but Higher Than With SGLT-2 InhibitorsGI Risks Similar Among GLP-1 Drugs, but Higher Than With SGLT-2 Inhibitors
(MedPage Today) — Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 diabetes, although all higher than seen with sodium-glucose cotransporter 2 (SGLT-2) inhibitors, according… (MedPage Today) — Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type Read More
STAT+: Novo Nordisk spent millions on weight loss searches that took people to its Ozempic website, analysis foundSTAT+: Novo Nordisk spent millions on weight loss searches that took people to its Ozempic website, analysis found
Over a recent two-year period, Novo Nordisk spent an estimated $7.5 million on more than 15,000 paid keywords related to weight loss searches and generated more than 2.4 million visits to Ozempic.com, even though the medicine is not approved to combat obesity, a new analysis found. Notably, more than 3,500 keywords contained no mention of Read More
Clinical trial sees dramatic results using radiation to treat breast cancerClinical trial sees dramatic results using radiation to treat breast cancer
Almost immediately after Theresa Greco was diagnosed with breast cancer in March, doctors asked her whether she wanted to participate in a clinical trial. The trial would do high-powered radiation targeted at her tumor prior to surgery, rather than the typical protocol of doing surgery first, then broader radiation.
Adjuvant Endocrine Therapy With Ovarian Function Suppression (OFS) by Breast Cancer IndexAdjuvant Endocrine Therapy With Ovarian Function Suppression (OFS) by Breast Cancer Index
This prognostic study assesses assess the Breast Cancer Index as a predictive biomarker of benefit from exemestane plus ovarian function suppression vs tamoxifen plus OFS and as a prognostic biomarker for premenopausal patients with hormone receptor–positive breast cancer.
Personalizing Adjuvant Endocrine Therapy for Breast CancerPersonalizing Adjuvant Endocrine Therapy for Breast Cancer
Oncology
Could a cancer vaccine developed long ago hold the key to long-term survival in breast cancer?Could a cancer vaccine developed long ago hold the key to long-term survival in breast cancer?
A small group of women with advanced breast cancer received a vaccine via a clinical trial more than 20 years ago. Today, they’re all still alive. Scientists say that kind of long-term survival is almost unheard of for patients with metastatic breast cancer, and it’s what caught the attention of researchers now.
Ozempic and Wegovy protect the heart, even without weight lossOzempic and Wegovy protect the heart, even without weight loss
Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems tied not just to slimming down but to deeper biological effects on inflammation, blood pressure, and vessel health. Researchers say this could expand who Read More